Listing 1 - 10 of 19 | << page >> |
Sort by
|
Choose an application
Herpes simplex --- Herpes simplex virus --- Herpes-simplex-virus --- Herpès simple
Choose an application
Le virus de l’herpès simplex, que ce soit le simplex 1 (HSV- 1) ou le simplex 2 (HSV-2) est véritablement un fléau mondial. On estimait, en 2012, que 67% de la population internationale infectée par le HSV-1 et que 417 millions de personnes portaient le HSV-2. Ces virus sont responsables dans la plupart des cas de lésions désagréables au niveau du visage et des parties génitales, mais dans certains cas provoquent des complications graves telles qu'une encéphalite ou méningite et un herpès néonatal parfois pour le nourrisson. Les traitements actuels sontmais consistent seulement à atténuer les symptômes lors d'une primo-infection ou récurrence. C'est pourquoi les firmes pharmaceutiques sont à la recherche d’une recherche s’est concentrée en premier sur l'approche prophylactique, mais les résultats des études très décevants. Suite à ces résultats, les firmes pharmaceutiques se focalisent aujourd'hui sur un vaccin thérapeutique afin de diminuer la sévérité et la fréquence des épisodes de et excrétions virales. Nous allons découvrir quelles ont été les raisons possibles de l'échec du vaccin prophylactique, l'avancement de la recherche etdéveloppement vaccin thérapeutique pour finalement tenter de répondre à la question suivante : le vaccin thérapeutique pourrait-il son épingle du jeu ? The virus herpes simplex 1 (HSV-1) or simplex 2 (HSV-2) are a worldwide scourge. In 2012, it was estimated that 67% of the international population was infected by HSV-1 and 417 million people were living with HSV-2. In general, those viruses are responsible for unpleasant facials and genitals lesions. In some cases, they cause serious complications such as encephalitis or meningitis and neonatal herpes, which can be fatal for the new born. The current treatments are effective but they only attenuate the symptoms during a primary infection or viral recurrence. It is why pharmaceutical companies are looking for a vaccine. The research primarily focused on the prophylactic approach but the results of the studies were very disappointing. Following these results, pharmaceutical companies are now focusing on a therapeutic vaccine to reduce the severity and frequency of recurrence episodes and viral shedding. We will discover which are the possible reasons for the failure of the prophylactic vaccine and the advancement of research and development of the therapeutic vaccine. We will try to finally answer the following question: the therapeutic vaccine will be able to emerge?
Herpes Simplex Virus Vaccines --- Antibiotic Prophylaxis --- Vaccination
Choose an application
Choose an application
Herpes simplex --- Herpes simplex virus --- Herpes-simplex-virus --- Herpès simple --- Herpes Simplex --- Immunology --- Prevention & control --- Immunology. --- Prevention & control.
Choose an application
Choose an application
Choose an application
Keratitis, Dendritic. --- Simplexvirus --- Herpes simplex virus --- -Keratitis --- -Cornea --- Cornea --- Eye --- Herpesvirus hominis --- HSV (Virus) --- Herpesviruses --- Furrow Keratitis --- Keratitis, Furrow --- Dendritic Keratitides --- Dendritic Keratitis --- Furrow Keratitides --- Keratitides, Dendritic --- Keratitides, Furrow --- pathogenicity. --- Congresses --- Inflammation --- Diseases --- -pathogenicity. --- -Furrow Keratitis --- Keratitis --- Keratitis, Dendritic --- pathogenicity --- Hoornvliesontsteking. (Congres) --- Herpes simplex (Infection à). (Congrès) --- Kératite. (Congrès) --- Herpes simplex-infecties. (Congres) --- Herpes zoster - ophtalmicus
Choose an application
Herpes genitalis. --- Herpes simplex virus. --- Sexually transmitted diseases. --- Sexual diseases --- Sexually transmissible infections --- Sexually transmitted infections --- STDs (Diseases) --- STIs (Sexually transmitted infections) --- VD (Disease) --- Venereal diseases --- Communicable diseases --- Sexual health --- Herpesvirus hominis --- HSV (Virus) --- Herpesviruses --- Genital herpes --- Herpes progenitalis --- Herpes simplex, Genital --- Herpes simplex --- Sexually transmitted diseases
Choose an application
A Special Issue in memory of Randall J. Cohrs, Ph.D. Topics include original research reports on a variety of viruses as well as reviews and commentaries on Randy’s contributions to many investigations.
Research & information: general --- Biology, life sciences --- varicella-zoster virus --- Oka strain --- human herpesvirus 6 --- human herpesvirus 7 --- corticosteroids --- serious adverse event --- herpes zoster --- IL-6 --- IL-10 --- innate immunity --- VLT --- VLT-ORF63 --- CRISPR/Cas9 --- BAC mutagenesis --- flavivirus --- SARS-CoV-2 --- pandemic preparedness --- host–virus interactions --- prion --- vaccines --- interferon lambda --- virus --- herpes simplex virus type 1 --- herpes simplex virus type 2 --- neonatal herpesvirus infection --- HSV UL6 --- herpesvirus encephalitis --- herpesvirus hepatitis --- acyclovir --- HerpeSelect test --- viral sequencing --- HELLP syndrome --- lipids --- dengue virus --- acyl-CoA --- acyl-CoA thioesterase --- fatty acids --- membranes --- rheostat --- fatty acyl-CoA --- Marek’s disease virus --- live-cell genome visualization --- lytic replication --- T cells --- latency --- genome integration --- TetO/TetR system --- varicella zoster virus --- reactivation --- genome cleavage --- AAV --- antiviral therapies --- HSV-1 --- cornea --- trigeminal ganglia --- interferon-γ --- interferon stimulatory genes --- TRIM21 --- HSV --- EBV --- KSHV --- MHV68 --- PIC --- transcription --- productive elongation --- mRNA --- rRNA --- tRNA --- herpes --- viral reactivation --- spaceflight --- dermatitis --- stress --- immune depression --- antiviral drugs --- bacterial artificial chromosome --- luciferase --- bioluminescence imaging --- skin organ culture --- humanized mice --- β-Coronavirus --- mouse hepatitis virus-A59/MHV-A59 --- mouse hepatitis virus-2/MHV2 spike protein --- fusion peptide/FP --- cell-to-cell fusion (fusogenicity) --- neuropathogenesis --- hepatitis --- demyelination --- structural rigidity --- simian varicella virus --- herpesvirus --- varicella --- VZV --- neuro-attenuated --- ORF7 --- vaccine --- n/a --- antiviral --- COVID-19 --- drug discovery --- coronavirus --- spike protein --- Mpro --- RdRp --- PLpro --- skin --- epidermis --- keratinocytes --- epidermal differentiation --- cutaneous blistering lesions --- keratins --- autophagy --- immunity --- human neuron culture --- non-coding RNA --- CD8 T cell --- T-cell epitope --- NK cell --- KIR3DL1 --- HLA-B*57:01 --- herpes simplex virus --- zoster --- skin pathogenesis --- HSV-2 --- neurons --- cell culture --- varicella-zoster --- gene expression --- ganglion --- autopsy --- saliva --- salivary VZV DNA --- dengue viruses --- Aedes aegypti --- adaptive mutation --- host-virus interactions --- Marek's disease virus
Choose an application
The materials published in the Special Issue reflect the real diversity of echinoderm metabolites and cover most of their specific classes and biomedical potential as antioxidant, antiviral, anticancer, and even anticoagulant preparations. The metabolites include sea urchin naphtoquinoid pigments and their semi-synthetic derivatives, sea cucumber triterpene glycosides, esters of polyhydroxysteroids from starfish, sea urchins free sterols, and sea cucumber fucosylated chondroitin sulfates. This Special Issue, “Echinoderm Metabolites: Structure, Functions, and Biomedical Perspectives”, is a collection of articles about different scientific aspects concerning low molecular weight and biopolymer metabolites from echinoderms, including their isolation and chemical structures, biological activities, biosynthesis and evolution, biological functions, and obtaining of semi-synthetic derivatives of biologically active natural products. This Special Issue includes materials about sea urchin naphtoquinoid pigments and their semi-synthetic derivatives, sea cucumber triterpene glycosides, esters of polyhydroxysteroids from starfish, sea urchin free sterols, and sea cucumber fucosylated chondroitin sulfates.
prostate cancer --- thioglucoside conjugates --- natural products --- sea urchins --- glucose uptake --- polyhydroxysteroidal esters --- NMR spectra --- fatty acids --- starfish --- Ceramaster patagonicus --- cytostatic activity --- soft agar assay --- wound healing assay --- Colochirus quadrangularis --- triterpene glycosides --- quadrangularisosides --- sea cucumber --- cytotoxic activity --- Holothuria hilla --- Paracaudina chilensis --- fucosylated chondroitin sulfate --- anticoagulant activity --- echinochrome A --- echinamine A --- echinamine B --- herpes simplex virus type 1 --- Vero cells --- glycoprotein gD --- molecular docking --- Thyonidium kurilensis --- kurilosides --- Thenea muricata --- Aplysina sp. --- Pseudoanthomastus agaricus --- Montastraea cavernosa --- Buccinum sp. --- Pasiphaea tarda --- Phormosoma placenta --- Echinometra lucunter --- sterols --- gas chromatography --- mass spectrometry --- neuroblastoma Neuro-2a cells --- 5,8-dihydroxy-1,4-naphthoquinone --- O-glucoside --- thiomethylglycoside --- QSAR --- n/a
Listing 1 - 10 of 19 | << page >> |
Sort by
|